Literature DB >> 27880072

Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.

Christian Schneeweis1, Matthias Wirth1, Dieter Saur1,2, Maximilian Reichert1, Günter Schneider1,2.   

Abstract

EGFR signaling has a critical role in oncogenic KRAS-driven tumorigenesis of the pancreas, whereas it is dispensable in other organs. The complex signaling network engaged by oncogenic KRAS and its modulation by EGFR signaling, remains incompletely understood. In order to study early signaling events activated by oncogenic KRAS in the pancreas, we recently developed a novel model system based on murine primary pancreatic epithelial cells enabling the time-specific expression of mutant KrasG12D from its endogenous promoter. Here, we discuss our findings of a KrasG12D-induced autocrine EGFR loop, how this loop is integrated by the MYC oncogene, and point to possible translational implications.

Entities:  

Keywords:  EGFR; MYC; autocrine signaling; kras; pancreatic cancer

Mesh:

Substances:

Year:  2017        PMID: 27880072      PMCID: PMC6205075          DOI: 10.1080/21541248.2016.1262935

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  56 in total

Review 1.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

Review 2.  MYC and transcription elongation.

Authors:  Peter B Rahl; Richard A Young
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 3.  Concepts to Target MYC in Pancreatic Cancer.

Authors:  Matthias Wirth; Siavosh Mahboobi; Oliver H Krämer; Günter Schneider
Journal:  Mol Cancer Ther       Date:  2016-07-12       Impact factor: 6.261

4.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

Review 5.  Taming of the beast: shaping Myc-dependent amplification.

Authors:  Elmar Wolf; Charles Y Lin; Martin Eilers; David L Levens
Journal:  Trends Cell Biol       Date:  2014-12-01       Impact factor: 20.808

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

7.  Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.

Authors:  Janel L Kopp; Guido von Figura; Erin Mayes; Fen-Fen Liu; Claire L Dubois; John P Morris; Fong Cheng Pan; Haruhiko Akiyama; Christopher V E Wright; Kristin Jensen; Matthias Hebrok; Maike Sander
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

8.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.

Authors:  Carmen Guerra; Alberto J Schuhmacher; Marta Cañamero; Paul J Grippo; Lena Verdaguer; Lucía Pérez-Gallego; Pierre Dubus; Eric P Sandgren; Mariano Barbacid
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

9.  Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Kathleen E DelGiorno; Lizhi Zhang; Michael Leitges; Howard C Crawford; Michael P Murphy; Peter Storz
Journal:  Cell Rep       Date:  2016-03-03       Impact factor: 9.423

10.  Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy.

Authors:  Mahima Swamy; Shalini Pathak; Katarzyna M Grzes; Sebastian Damerow; Linda V Sinclair; Daan M F van Aalten; Doreen A Cantrell
Journal:  Nat Immunol       Date:  2016-04-25       Impact factor: 25.606

View more
  6 in total

Review 1.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

Review 2.  Tissue-specific tumorigenesis: context matters.

Authors:  Günter Schneider; Marc Schmidt-Supprian; Roland Rad; Dieter Saur
Journal:  Nat Rev Cancer       Date:  2017-03-03       Impact factor: 60.716

Review 3.  Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.

Authors:  Michael Orth; Philipp Metzger; Sabine Gerum; Julia Mayerle; Günter Schneider; Claus Belka; Maximilian Schnurr; Kirsten Lauber
Journal:  Radiat Oncol       Date:  2019-08-08       Impact factor: 3.481

4.  KrasG12D induces changes in chromatin territories that differentially impact early nuclear reprogramming in pancreatic cells.

Authors:  Angela J Mathison; Romica Kerketta; Thiago Milech de Assuncao; Elise Leverence; Atefeh Zeighami; Guillermo Urrutia; Timothy J Stodola; Marina Pasca di Magliano; Juan L Iovanna; Michael T Zimmermann; Gwen Lomberk; Raul Urrutia
Journal:  Genome Biol       Date:  2021-10-14       Impact factor: 13.583

5.  MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.

Authors:  Zhou Luan; Yoshihiro Morimoto; Atsushi Fushimi; Nami Yamashita; Wenhao Suo; Atrayee Bhattacharya; Masayuki Hagiwara; Caining Jin; Donald Kufe
Journal:  Carcinogenesis       Date:  2022-02-11       Impact factor: 4.944

6.  MTOR inhibitor-based combination therapies for pancreatic cancer.

Authors:  Zonera Hassan; Christian Schneeweis; Matthias Wirth; Christian Veltkamp; Zahra Dantes; Benedikt Feuerecker; Güralp O Ceyhan; Shirley K Knauer; Wilko Weichert; Roland M Schmid; Roland Stauber; Alexander Arlt; Oliver H Krämer; Roland Rad; Maximilian Reichert; Dieter Saur; Günter Schneider
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 9.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.